Skip to main content
All lobbying clients

ORCHARD THERAPEUTICS NORTH AMERICA

Lobbying client · Massachusetts · filed 2025 to 2026

Biopharmaceutical company.

$3,050,000 Reported spend
40 Filings counted
6 Outside firms hired
7 Bills named

Spend is reported income plus in-house expenses across 40 filings. 2 further filings for this client were restated by a later amendment and are left out of every total here. The LDA keeps a separate client record for every registrant that files for a client, so this page adds up 7 records, one per registrant listed below. Records are combined when the client name matches once case, punctuation and endings such as Inc. or LLC are set aside; for a city, county or port the state has to match as well.

 Who filed for this client 7

Spend per registrant: fees an outside firm reported, or the costs the client reported for lobbying in-house. The rows add up to the total above.

 Bills named in these filings 7
  • H.R. 1509
    Accelerating Kids’ Access to Care Act of 2025
    11 filings
  • S. 752
    Accelerating Kids’ Access to Care Act
    8 filings
  • H.R. 1262
    Mikaela Naylon Give Kids a Chance Act
    4 filings
  • H.R. 7871
    MVP Act
    3 filings
  • S. 1637
    MVP Act
    2 filings
  • H.R. 2666
    Medicaid VBPs for Patients Act
    1 filing
  • H.R. 10571
    Surge to Save Newborns Act
    1 filing
 Reported by year 2 years
  • 2026 $1,280,000 16 filings
  • 2025 $1,770,000 24 filings
 Issues lobbied 5

The count is how many filings named that issue area. A filing reports one lump figure covering every issue on it, so the money above cannot be split between them.

 Agencies and chambers lobbied 6
  • HOUSE OF REPRESENTATIVES 32
  • SENATE 32
  • Health & Human Services, Dept of (HHS) 15
  • Food & Drug Administration (FDA) 7
  • Centers For Medicare and Medicaid Services (CMS) 6
  • Executive Office of the President (EOP) 4
 Recent filings 42 total
Q3 report
LEAVITT PARTNERS, LLC
3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $10,000 income · posted Oct 20, 2026
View → Q3 report
ORCHARD THERAPEUTICS NORTH AMERICA
3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $240,000 expenses · posted Oct 19, 2026
View → Q3 report
CORCORAN & ASSOCIATES, INC. DBA CORCORAN PARTNERS
3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $30,000 income · posted Oct 19, 2026
View → Q3 report
JEFFREY J. KIMBELL & ASSOCIATES, INC.
3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $30,000 income · posted Oct 17, 2026
View → Q3 report
S-3 GROUP
3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $60,000 income · posted Oct 16, 2026
View → Q2 report
JEFFREY J. KIMBELL & ASSOCIATES, INC.
2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $10,000 income · posted Jul 20, 2026
View → Q2 report
S-3 GROUP
2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $60,000 income · posted Jul 17, 2026
View → Q2 report
ORCHARD THERAPEUTICS NORTH AMERICA
2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $190,000 expenses · posted Jul 17, 2026
View → Q2 report
CORCORAN & ASSOCIATES, INC. DBA CORCORAN PARTNERS
2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $30,000 income · posted Jul 16, 2026
View → Q2 report
LEAVITT PARTNERS, LLC
2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $20,000 income · posted Jul 15, 2026
View → Q1 amendment
ORCHARD THERAPEUTICS NORTH AMERICA
1st Quarter 2026 (Jan 1 - Mar 31) · House · Senate · $470,000 expenses · posted Apr 29, 2026
View → Q1 report
JEFFREY J. KIMBELL & ASSOCIATES, INC.
1st Quarter 2026 (Jan 1 - Mar 31) · House · Senate · $10,000 income · posted Apr 20, 2026
View → Q1 report
LEAVITT PARTNERS, LLC
1st Quarter 2026 (Jan 1 - Mar 31) · House · Senate · $30,000 income · posted Apr 20, 2026
View → Q1 report
CORCORAN & ASSOCIATES, INC. DBA CORCORAN PARTNERS
1st Quarter 2026 (Jan 1 - Mar 31) · House · Senate · $30,000 income · posted Apr 20, 2026
View → Q1 report
ORCHARD THERAPEUTICS NORTH AMERICA Amended
1st Quarter 2026 (Jan 1 - Mar 31) · House · Senate · $350,000 expenses · posted Apr 17, 2026
View → Q1 report
S-3 GROUP
1st Quarter 2026 (Jan 1 - Mar 31) · House · Senate · $60,000 income · posted Apr 17, 2026
View → Q2 amendment
ORCHARD THERAPEUTICS NORTH AMERICA
2nd Quarter 2025 (Apr 1 - June 30) · House · Senate · $430,000 expenses · posted Mar 13, 2026
View → Registration
JEFFREY J. KIMBELL & ASSOCIATES, INC.
1st Quarter 2026 (Jan 1 - Mar 31) · posted Feb 13, 2026
View → Q4 termination
THEGROUP DC, LLC
4th Quarter 2025 (Oct 1 - Dec 31) · House · Senate · $50,000 income · posted Jan 20, 2026
View → Q4 report
ORCHARD THERAPEUTICS NORTH AMERICA
4th Quarter 2025 (Oct 1 - Dec 31) · House · Senate · $260,000 expenses · posted Jan 20, 2026
View →

Showing the 20 most recent of 42 filings. Search the explorer for "ORCHARD THERAPEUTICS NORTH AMERICA".

 Foreign entities disclosed 4
  • ORCHARD THERAPEUTICS LIMITED United Kingdom named on 5 filings · highest disclosed ownership 100% · largest disclosed contribution $0
  • KYOWA KIRIN INTERNATIONAL PLC United Kingdom named on 4 filings · highest disclosed ownership 100% · largest disclosed contribution $20,000
  • ORCHARD THERAPEUTICS (EUROPE) LIMITED United Kingdom named on 2 filings · highest disclosed ownership 100% · largest disclosed contribution $880,000
  • KYOWA KIRIN INTERNATIONAL, PLC United Kingdom named on 1 filing · highest disclosed ownership 100% · largest disclosed contribution $0

Section 7 of the LD-2: a foreign company or government that owns part of the client, pays toward the lobbying, or benefits from it. Figures are the highest single disclosure across these filings, not a sum: the same stake is re-disclosed each quarter.

Keep going

Filings through , the newest posted date on this record. Source: federal Lobbying Disclosure Act filings, synced daily. Money is self-reported by the filer and often rounded. Lobbying is legal, disclosed activity.

Report a problem